...
首页> 外文期刊>Leukemia and lymphoma >Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas
【24h】

Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas

机译:恶性造血细胞系:双重感染B细胞淋巴瘤的体外模型

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Mature B-cell lymphomas with concurrent rearrangements of MYC and BCL2 (more rarely BCL6), double-hit lymphomas (DHLs), form a heterogeneous group. Recent studies have shown that DHLs often present with an aggressive clinical course and a poor prognosis with standard therapy. This distinct clinical entity would benefit from more detailed pathobiological characterization to develop improved treatment options. Lymphoma cell lines are important and informative research tools. Several cell lines have been established from B-cell lymphoma patients harboring MYC rearrangements combined with either (double-hit) or both (triple-hit) BCL2 or BCL6 translocations. All rearrangements have been detected by cytogenetics and validated by FISH. These cell lines provide preclinical models for basic and translational research which speed development of effective treatment strategies.
机译:伴有MYC和BCL2重排的成熟B细胞淋巴瘤(很少见BCL6),重击淋巴瘤(DHL)形成异质性组。最近的研究表明,DHL经常表现出侵袭性的临床病程,而标准疗法的预后却很差。这种独特的临床实体将受益于更详细的病理生物学特征,以开发改良的治疗方案。淋巴瘤细胞系是重要且信息丰富的研究工具。从携带MYC重排并结合(两次打击)或两者(三次打击)BCL2或BCL6易位的B细胞淋巴瘤患者中已经建立了几种细胞系。所有重排均已通过细胞遗传学检测并通过FISH验证。这些细胞系为基础研究和转化研究提供了临床前模型,可加快有效治疗策略的开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号